NICE deals final blow for Roche's Avastin in breast cancer
This article was originally published in Scrip
Executive Summary
Roche's Avastin (bevacizumab) has again fallen foul of NICE, the health technology appraisal body for England and Wales. The institute has today published final guidance rejecting the drug when used with Roche’s Xeloda (capecitabine) in first-line treatment of metastatic breast cancer.